Pelthos Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Revenue	7.41	-	-	-	-	0.2
Cost of Revenue	2.28	-	-	0.39	0.21	0.14
Gross Profit	5.13	-	-	-0.39	-0.21	0.06
Selling, General & Admin	24.5	6.39	4.28	1.93	0.63	1.42
Research & Development	1.18	1.18	2.58	-	-	-
Operating Expenses	26.36	7.57	6.86	1.93	0.63	1.42
Operating Income	-21.23	-7.57	-6.86	-2.32	-0.84	-1.35
Interest Expense	-2.2	-0.79	-0.52	-0.14	-0	-0
Other Non Operating Income (Expenses)	0.04	0.04	-	-	-	0.69
EBT Excluding Unusual Items	-23.39	-8.32	-7.38	-2.46	-0.84	-0.66
Legal Settlements	0.36	0.36	-	-	-	-
Other Unusual Items	-	-	-	-	0.24	-
Pretax Income	-24.05	-7.96	-7.38	-2.46	-0.6	-0.66
Net Income	-23.58	-7.96	-7.38	-2.46	-0.6	-0.66
Net Income to Common	-23.58	-7.96	-7.38	-2.46	-0.6	-0.66
Shares Outstanding (Basic)	1	1	0	0	-	-
Shares Outstanding (Diluted)	1	1	0	0	-	-
Shares Change (YoY)	170.72%	336.69%	193.25%	-	-	-
EPS (Basic)	-19.07	-14.27	-57.82	-56.48	-	-
EPS (Diluted)	-19.07	-14.27	-57.82	-56.48	-	-
Gross Margin	69.27%	-	-	-	-	30.69%
Operating Margin	-286.65%	-	-	-	-	-677.16%
Profit Margin	-318.41%	-	-	-	-	-330.40%
EBITDA	-	-	-	-1.63	-	-
D&A For EBITDA	-	-	-	0.69	-	-
EBIT	-21.23	-7.57	-6.86	-2.32	-0.84	-1.35
Revenue as Reported	7.41	-	-	-	-	0.2

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q